Weight gain in hormone receptor-positive (HR+) early-stage breast cancer: is it menopausal status or something else?

Abstract:

PURPOSE:This study investigates weight trajectories in pre- versus postmenopausal breast cancer (BC) survivors diagnosed with hormone receptor-positive tumors, with a specific focus on discerning menopausal status and type of endocrine treatment (ET) as risk factors for weight gain during ET. METHODS:We conducted a retrospective review of electronic medical records. Descriptive statistics and Chi-squared and t tests were used to compare pre- and postmenopausal women. Chi-squared tests and ANOVA were used for within-group associations between patient characteristics and weight trajectories. Log-binomial regression models were used to estimate relative risk for weight gain. RESULTS:The final sample was 32% premenopausal (n = 140) and 68% postmenopausal (n = 298). Relative risk (RR) for weight gain during ET was highest in women who were premenopausal (RR = 1.29, 1.03-1.52) and had Stage 3 BC (RR = 2.12, 1.59-2.82), mastectomy (RR = 1.49, 1.19-1.88), axillary node dissection (RR = 1.39, 1.11-1.73), and chemotherapy (RR = 1.80, 1.37-2.36). For each kg of weight gained between BC diagnosis and start of ET, and for each additional year of age, RR of gaining weight during ET decreased (RR = 0.98, 0.97-0.99, and RR = 0.99, 0.98-0.99, respectively). Menopausal status and type of ET were not significant predictors of weight gain. In multivariable analysis, only weight loss between BC diagnosis and start of ET was significant. CONCLUSION:The association of weight loss prior to ET and subsequent substantial weight gain during ET warrants further investigation.

authors

Nyrop KA,Deal AM,Lee JT,Muss HB,Choi SK,Wheless A,Carey LA,Shachar SS

doi

10.1007/s10549-017-4501-4

subject

Has Abstract

pub_date

2018-01-01 00:00:00

pages

235-248

issue

1

eissn

0167-6806

issn

1573-7217

pii

10.1007/s10549-017-4501-4

journal_volume

167

pub_type

杂志文章
  • Who may benefit from preoperative breast MRI? A single-center analysis of 1102 consecutive patients with primary breast cancer.

    abstract::Several authors question the potential benefit of preoperative magnetic resonance imaging (MRI) against the background of possible overdiagnosis, false-positive findings, and unnecessary resections in patients with newly diagnosed breast cancer. In order to reveal a better selection of patients who should undergo preo...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-015-3556-3

    authors: Debald M,Abramian A,Nemes L,Döbler M,Kaiser C,Keyver-Paik MD,Leutner C,Höller T,Braun M,Kuhl C,Kuhn W,Schild HH

    更新日期:2015-10-01 00:00:00

  • Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer.

    abstract::The development of recombinant vaccines for specific immunotherapy of carcinoma represents a novel approach for the treatment of breast cancer and other tumor types. This article reviews the various parameters that should be considered in the development of recombinant vaccines. Several breast cancer associated antige...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/BF01803781

    authors: Schlom J,Kantor J,Abrams S,Tsang KY,Panicali D,Hamilton JM

    更新日期:1996-01-01 00:00:00

  • Measurement of occupied and non-occupied epidermal growth factor receptor sites in 216 human breast cancer biopsies.

    abstract::The epidermal growth factor (EGF) is one of several growth factors involved in normal breast epithelial development and tumor proliferation. EGF and EGF-like peptide TGF alpha bind and activate the same membrane receptor protein. This receptor (EGF-R) has been recently studied in breast tumor biopsies and its detectab...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01834623

    authors: Falette N,Lefebvre MF,Meggouh F,Eynard M,Garin E,Saez S

    更新日期:1992-03-01 00:00:00

  • Comparison of resection margin status after single or double radiopaque marker insertion for tumor localization in breast cancer patients receiving neoadjuvant chemotherapy.

    abstract:PURPOSE:Insertion of radiopaque markers is helpful for tumor localization in patients receiving neoadjuvant chemotherapy (NAC) followed by breast-conserving surgery (BCS). The aim of this retrospective study was to investigate the pathologic margin status in patients with single or double marker insertion. METHODS:We ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05907-9

    authors: Cha C,Lee J,Kim D,Park S,Bae SJ,Eun NL,Ahn SG,Son EJ,Jeong J

    更新日期:2020-12-01 00:00:00

  • Management of brain metastases in breast cancer: a review of current practices and emerging treatments.

    abstract:PURPOSE:Breast cancer brain metastases (BCBM) are becoming an increasingly common diagnosis due to improved systemic control and more routine surveillance imaging. Treatment continues to require a multidisciplinary approach managing systemic and intracranial disease burden. Although, improvements have been made in the ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-020-05552-2

    authors: Mills MN,Figura NB,Arrington JA,Yu HM,Etame AB,Vogelbaum MA,Soliman H,Czerniecki BJ,Forsyth PA,Han HS,Ahmed KA

    更新日期:2020-04-01 00:00:00

  • Fat necrosis of the breast in the accelerated partial breast irradiation era: the need for a universal grading system.

    abstract::Fat necrosis of the breast is increasingly reported and used as a trial endpoint in the treatment of breast cancer with accelerated partial breast irradiation (APBI). Yet, there is no universal toxicity scoring system within the latest version of the Common Terminology Criteria for Adverse Events (CTCAE v4.0). This re...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-013-2611-1

    authors: Russo AL,Taghian AG

    更新日期:2013-07-01 00:00:00

  • Contribution of germline mutations in cancer predisposition genes to tumor etiology in young women diagnosed with invasive breast cancer.

    abstract:PURPOSE:Although breast cancer in young women accounts for <10% of diagnoses annually, tumors in young patients exhibit more aggressive characteristics and higher mortality rates. Determination of the frequency of germline mutations in cancer predisposition genes is needed to improve the understanding of breast cancer ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4291-8

    authors: Rummel SK,Lovejoy L,Shriver CD,Ellsworth RE

    更新日期:2017-08-01 00:00:00

  • Gene-based analysis of the fibroblast growth factor receptor signaling pathway in relation to breast cancer in African American women: the AMBER consortium.

    abstract::We conducted gene-based analysis in 26 genes in the FGFR signaling pathway to identify genes carrying genetic variation affecting risk of breast cancer and the specific estrogen receptor (ER) subtypes. Tagging single-nucleotide polymorphisms (SNPs) for each gene were selected and genotyped on a customized Illumina Exo...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-015-3672-0

    authors: Ruiz-Narváez EA,Haddad SA,Lunetta KL,Yao S,Bensen JT,Sucheston-Campbell LE,Hong CC,Haiman CA,Olshan AF,Ambrosone CB,Palmer JR

    更新日期:2016-01-01 00:00:00

  • Clinicopathological significance of lipocalin 2 nuclear expression in invasive breast cancer.

    abstract:PURPOSE:The epithelial-mesenchymal transition (EMT) plays a key role in breast cancer progression and metastasis. Lipocalin 2 (LCN2) is involved in the regulation of EMT. The aim of this study was to investigate the clinicopathological significance of LCN2 expression in breast cancer. METHODS:The expression of LCN2 pr...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05488-2

    authors: Kurozumi S,Alsaeed S,Orah N,Miligy IM,Joseph C,Aljohani A,Toss MS,Fujii T,Shirabe K,Green AR,Aleskandarany MA,Rakha EA

    更新日期:2020-02-01 00:00:00

  • Clinical and pathological characterization of HER2 mutations in human breast cancer: a systematic review of the literature.

    abstract:PURPOSE:HER2 gene is a member of the epidermal growth factor receptor (EGFR) family. Across different malignancies, aberrations of HER2 gene commonly correspond to gain-of-function alterations leading to increased receptor signaling. METHODS:We have reviewed the literature currently available on HER2 mutations in huma...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-017-4419-x

    authors: Petrelli F,Tomasello G,Barni S,Lonati V,Passalacqua R,Ghidini M

    更新日期:2017-11-01 00:00:00

  • Transforming growth factorβ1 L10P variant plays an active role on the breast cancer susceptibility in Caucasian: evidence from 10,392 cases and 11,697 controls.

    abstract::In view of the essential role of transforming growth factorβ1 (TGFB1) on both inhibiting the development of early benign breast tumors as well as promoting tumor invasion, the association of TGFB1 L10P polymorphism and breast cancer risk has been widely reported, but results of previous studies were somewhat contradic...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析,评审

    doi:10.1007/s10549-010-0843-x

    authors: Ma X,Chen C,Xiong H,Li Y

    更新日期:2010-11-01 00:00:00

  • Pre-operative progesterone benefits operable breast cancer patients by modulating surgical stress.

    abstract:PURPOSE:We have reported a survival benefit of single injection of hydroxyprogesterone prior to surgery for primary tumour in patients with node-positive operable breast cancer. Hydroxyprogesterone was meant to recapitulate the luteal phase of menstrual cycle in these women. We wanted to understand the molecular basis ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-4749-3

    authors: Chatterjee S,Chaubal R,Maitra A,Gardi N,Dutt A,Gupta S,Badwe RA,Majumder PP,Pandey P

    更新日期:2018-07-01 00:00:00

  • Evaluation of phospho-histone H3 in Asian triple-negative breast cancer using multiplex immunofluorescence.

    abstract:PURPOSE:We used multiplex immunofluorescence (mIF) to determine whether mitotic rate represents an independent prognostic marker in triple-negative breast cancer (TNBC). Secondary aims were to confirm the prognostic significance of immune cells in TNBC, and to investigate the relationship between immune cells and proli...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05396-5

    authors: Lai CPT,Yeong JPS,Tan AS,Ong CHC,Lee B,Lim JCT,Thike AA,Iqbal J,Dent RA,Lim EH,Tan PH

    更新日期:2019-11-01 00:00:00

  • Spindle cell lesions of the breast--the pathologic differential diagnosis.

    abstract::Spindle cell lesions of the breast represent an interesting diagnostic problem, as the differential diagnoses are wide. Diagnosing this is particularly problematic but important when encountered in a needle core biopsy, as treatments of different entities are different. In the histologic assessment of spindle cell les...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-007-9652-2

    authors: Tse GM,Tan PH,Lui PC,Putti TC

    更新日期:2008-05-01 00:00:00

  • Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy.

    abstract::Triple-negative breast cancers lack estrogen receptor α (ERα), progesterone receptor, and do not overexpress human epidermal growth factor receptor 2 (Her-2). They are neither susceptible to endocrine therapy nor to a therapy using the anti-Her-2 antibody, trastuzumab. Therefore, an efficient targeted therapy is warra...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-012-1968-x

    authors: Girgert R,Emons G,Gründker C

    更新日期:2012-07-01 00:00:00

  • Growth kinetics of four human breast carcinomas grown in nude mice.

    abstract::The immune-deficient nude mouse with human tumor xenografts is an appropriate model system for performing detailed growth kinetic examinations. In the present study one estrogen and progesterone receptor-negative (T60) and three receptor-positive (Br-10, MCF-7, T61) human breast cancer xenografts in nude mice were inv...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01810740

    authors: Spang-Thomsen M,Rygaard K,Hansen L,Halvorsen AC,Vindeløv LL,Brünner N

    更新日期:1989-11-01 00:00:00

  • Dietary intake from birth through adolescence in relation to risk of benign breast disease in young women.

    abstract:PURPOSE:Nutritional factors during different periods in life impact breast cancer risk. Because benign breast disease (BBD) is a well-established risk factor for breast cancer, we investigated childhood nutrition from birth through age 14 year and subsequent BBD. METHODS:A prospective cohort study of 9031 females, 9-1...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05323-8

    authors: Berkey CS,Tamimi RM,Willett WC,Rosner B,Hickey M,Toriola AT,Lindsay Frazier A,Colditz GA

    更新日期:2019-09-01 00:00:00

  • Sphingosine-1-phosphate, a novel second messenger involved in cell growth regulation and signal transduction, affects growth and invasiveness of human breast cancer cells.

    abstract::This review will focus on the role of sphingosine and its phosphorylated derivative sphingosine-1-phosphate (SPP) in cell growth regulation and signal transduction. We will show that many of the effects attributed to sphingosine in quiescent Swiss 3T3 fibroblasts are mediated via its conversion to SPP. We propose that...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/BF00666166

    authors: Spiegel S,Olivera A,Zhang H,Thompson EW,Su Y,Berger A

    更新日期:1994-01-01 00:00:00

  • Delayed versus immediate exercises following surgery for breast cancer: a systematic review.

    abstract:BACKGROUND:Seroma formation, wound healing and fluid drainage are a concern for both surgeons and patients. Excessive fluid production can result in seroma formation, and inadequate drainage of seromas is known to cause infection, pain, discomfort and longer periods of hospitalisation. Postoperative exercises given to ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-004-4727-9

    authors: Shamley DR,Barker K,Simonite V,Beardshaw A

    更新日期:2005-04-01 00:00:00

  • Body mass index, age at breast cancer diagnosis, and breast cancer subtype: a cross-sectional study.

    abstract:PURPOSE:Evidence suggests that premenopausal obesity decreases and postmenopausal obesity increases breast cancer risk. Because it is not well known whether this is subtype dependent, we studied the association between body mass index (BMI) and age at breast cancer diagnosis, or the probability of being diagnosed with ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4579-8

    authors: Brouckaert O,Van Asten K,Laenen A,Soubry A,Smeets A,Nevelstreen I,Vergote I,Wildiers H,Paridaens R,Van Limbergen E,Weltens C,Moerman P,Floris G,Neven P,Multidisciplinary breast centre Leuven.

    更新日期:2018-02-01 00:00:00

  • Sex steroid hormone levels in breast adipose tissue and serum in postmenopausal women.

    abstract::Elevated levels of circulating estrogens and androgens are linked to higher breast cancer risk among postmenopausal women; however, little is known about hormone levels within the breast. Hormone concentrations within the breast may not be reflected in the blood and are likely important contributors to breast carcinog...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1734-5

    authors: Falk RT,Gentzschein E,Stanczyk FZ,Garcia-Closas M,Figueroa JD,Ioffe OB,Lissowska J,Brinton LA,Sherman ME

    更新日期:2012-01-01 00:00:00

  • Chemotherapy for metastatic breast cancer. Comparison of clinical practice and cost of drugs in two cohorts of patients: 1994-1998 and 2003-2006.

    abstract::Although new chemotherapeutic drugs for metastatic breast cancer (MBC) have been approved over the past decade, it is unclear whether this has changed the overall outcome of patients. This study assessed the clinical and economic impacts of these drugs. We retrospectively studied MBC patients receiving chemotherapy in...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-1311-3

    authors: Galy G,Labidi-Galy SI,Perol D,Bachelot T,Ray-Coquard I,Tredan O,Biron P,Latour JF,Blay JY,Guastalla JP,Favier B

    更新日期:2011-07-01 00:00:00

  • Aromatase and its inhibitors in breast cancer treatment--overview and perspective.

    abstract::Estrogen has an important role in stimulating the growth of breast carcinomas. Inhibition of estrogen production is therefore a logical treatment strategy. A number of selective inhibitors have been developed against aromatase, a cytochrome P-450 enzyme which catalyzes the rate limiting step in the biosynthesis of est...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/BF00682736

    authors: Brodie AM,Santen RJ

    更新日期:1994-01-01 00:00:00

  • One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery).

    abstract::Genetic testing enables women at risk for hereditary breast and/or ovarian cancer to find out whether they have inherited the gene mutation (BRCA1/BRCA2), and if so, to opt for frequent surveillance and/or prophylactic surgery (bilateral mastectomy and/or oophorectomy). Here, a follow-up is described for 63 healthy wo...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1015269620265

    authors: Lodder LN,Frets PG,Trijsburg RW,Meijers-Heijboer EJ,Klijn JG,Seynaeve C,van Geel AN,Tilanus MM,Bartels CC,Verhoog LC,Brekelmans CT,Burger CW,Niermeijer MF

    更新日期:2002-05-01 00:00:00

  • Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"--20 years as a target for the treatment and prevention of cancer.

    abstract::In 1973, McGuire and Chamness (In: O'Malley BW and Means AR (ed) Receptors for Reproductive Hormones, Plenum Press) summarized their work on the estrogen receptor in animal and human breast tumors, and in so doing described a target for therapeutic intervention. At that time there were no clinically useful antiestroge...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/BF00713399

    authors: Jordan VC

    更新日期:1995-01-01 00:00:00

  • Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer.

    abstract::Adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) have proven highly effective in rapidly proliferating breast cancer (RPBC). It has also been seen that sequential administration of doxorubicin and CMF is superior to their alternation, especially in indolent tumors. In a phase III study, we evaluated w...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s10549-010-1257-5

    authors: Amadori D,Silvestrini R,De Lena M,Boccardo F,Rocca A,Scarpi E,Schittulli F,Brandi M,Maltoni R,Serra P,Ponzone R,Biglia N,Gianni L,Tienghi A,Valerio MR,Bonginelli P,Amaducci L,Faedi M,Baldini E,Paradiso A

    更新日期:2011-02-01 00:00:00

  • The prognostic value of NRF2 in breast cancer patients: a systematic review with meta-analysis.

    abstract:PURPOSE:Nuclear factor E2-related factor 2 (NRF2) is a transcription factor that plays a major role in the regulation of intracellular antioxidant response. The effect of NRF2 overexpression in many malignancies is still unclear and recent meta-analysis correlated NRF2 overexpression with poor prognosis in a variety of...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10549-019-05494-4

    authors: Almeida M,Soares M,Ramalhinho AC,Moutinho JF,Breitenfeld L,Pereira L

    更新日期:2020-02-01 00:00:00

  • Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer.

    abstract:BACKGROUND:TOP2A gene encodes topoisomerase II alpha, the direct molecular target of anthracyclines. This gene is frequently coamplified with HER2. The aims of this study were to analyse the pattern of TOP2A amplification and protein expression in relation to the molecular subgroups of breast cancers; and to define the...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9492-5

    authors: Arriola E,Rodriguez-Pinilla SM,Lambros MB,Jones RL,James M,Savage K,Smith IE,Dowsett M,Reis-Filho JS

    更新日期:2007-12-01 00:00:00

  • Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.

    abstract::Adjuvant therapy for hormone receptor (HR) positive postmenopausal breast cancer patients includes aromatase inhibitors (AI). While both the non-steroidal AI letrozole and the steroidal AI exemestane decrease serum estrogen concentrations, there is evidence that exemestane may be less detrimental to bone. We hypothesi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-015-3608-8

    authors: Oesterreich S,Henry NL,Kidwell KM,Van Poznak CH,Skaar TC,Dantzer J,Li L,Hangartner TN,Peacock M,Nguyen AT,Rae JM,Desta Z,Philips S,Storniolo AM,Stearns V,Hayes DF,Flockhart DA

    更新日期:2015-11-01 00:00:00

  • A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (

    abstract:PURPOSE:Suberoylanilide hydroxamic acid (SAHA; vorinostat), a small molecule inhibitor of histone deacetylase, attenuates signaling pathways known to confer trastuzumab resistance. A combination of SAHA and trastuzumab may be a promising strategy to improve the efficacy of trastuzumab against breast cancer. In this Pha...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4310-9

    authors: Goldstein LJ,Zhao F,Wang M,Swaby RF,Sparano JA,Meropol NJ,Bhalla KN,Pellegrino CM,Katherine Alpaugh R,Falkson CI,Klein P,Sledge GW

    更新日期:2017-09-01 00:00:00